Patent intelligence · US
US 6262069
1-amino-7-isoquinoline derivatives as serine protease inhibitors
1-amino-7-isoquinoline derivatives as serine protease inhibitors
Patent details — US 6262069
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jul 17, 2001
- Expiration
- Jul 12, 2021
- Applicant
- Protherics Molecular Design Ltd.
- Claims
- 28
- CPC classes
- A61K, A61K38/00
Quick answer
US 6262069 (1-amino-7-isoquinoline derivatives as serine protease inhibitors) is held by Protherics Molecular Design Ltd.. Status: expired. Granted Jul 17, 2001. Expires Jul 12, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Protherics Molecular Design Ltd.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K38/00
More from Protherics Molecular Design Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12378245
Crystalline forms of an RSK inhibitor
granted -
US 12297243
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
granted -
US 12291058
Dispersions for additive manufacturing comprising discrete carbon nanotubes
granted -
US 12268695
Betulin-containing birch bark extracts and their formulation
granted -
US 12247004
2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use
granted -
US 12065498
Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
granted -
US 12005194
Configurable oxygen concentrator and related method
granted -
US 11998571
Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease
granted
Frequently asked questions
What is US patent 6262069?
US 6262069 (1-amino-7-isoquinoline derivatives as serine protease inhibitors) is held by Protherics Molecular Design Ltd.. Status: expired. Granted Jul 17, 2001. Expires Jul 12, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6262069?
Protherics Molecular Design Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 201 pharmaceutical patents for this assignee.
When does US 6262069 expire?
Our index shows an expiration date of Jul 12, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.